Captrust Financial Advisors Sarepta Therapeutics, Inc. Transaction History
Captrust Financial Advisors
- $30.9 Billion
- Q2 2024
A detailed history of Captrust Financial Advisors transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 3,360 shares of SRPT stock, worth $408,609. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,360
Previous 2,422
38.73%
Holding current value
$408,609
Previous $313,000
69.33%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding SRPT
# of Institutions
548Shares Held
85.8MCall Options Held
3.64MPut Options Held
1.68M-
Black Rock Inc. New York, NY10.3MShares$1.26 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.04MShares$1.1 Billion0.03% of portfolio
-
Capital International Investors Los Angeles, CA4.32MShares$525 Million0.14% of portfolio
-
State Street Corp Boston, MA4.14MShares$504 Million0.03% of portfolio
-
Janus Henderson Group PLC London, X03.82MShares$464 Million0.33% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $10.6B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...